Long-term effects of cladribine tablets treatment on cognition, relapses, MRI, and safety outcomes in patients with relapsing multiple sclerosis: 4-year results from the CLARIFY-MS Extension study

被引：0
|
作者：
Selmaj, Krzysztof [1 ,2 ]
Langdon, Dawn [3 ]
Brochet, Bruno [4 ]
Solari, Alessandra [5 ]
Havrdova, Eva Kubala [6 ,7 ]
Patti, Francesco [8 ,9 ]
Piehl, Fredrik [10 ]
Smyk, Andrzej [11 ]
Lehn, Annette [11 ]
Nolting, Axel [11 ]
Montalban, Xavier [12 ]
Lechner-Scott, Jeannette [13 ,14 ]
机构：
[1] Ctr Neurol, Lodz, Poland
[2] Univ Warmia & Mazury, Dept Neurol, Olsztyn, Poland
[3] Royal Holloway Univ London, Dept Psychol, Egham, Surrey, England
[4] Univ Bordeaux, INSERM U 1215, Bordeaux, France
[5] Fdn IRCCS Ist Neurol Carlo Besta, Unit Neuroepidemiol, Milan, Italy
[6] Charles Univ Prague, Med Fac 1, Dept Neurol, Prague, Czech Republic
[7] Ctr Clin Neurosci, Prague, Czech Republic
[8] Univ Catania, Dept Med & Surg Sci & Adv Technol, GF Ingrassia, Catania, Italy
[9] Univ Catania, Azienda Osped Univ Policlin G Rodolico San Marco, Catania, Italy
[10] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
[11] Merck Healthcare KGaA, Darmstadt, Germany
[12] Univ Hosp Vall dHebron, Dept Neurol Neuroimmunol, Ctr Multiple Sclerosis Catalonia Cemcat, Barcelona, Spain
[13] Univ Newcastle, Newcastle, NSW, Australia
[14] John Hunter Hosp, Div Neurol, Newcastle, NSW, Australia
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P846/1650
引用
收藏
页码：655 / 657
页数：3
相关论文
共 50 条
  • [31] MRI Outcomes from the Long-term Extension Study of Tolebrutinib in Patients with Relapsing Multiple Sclerosis: 18-Month Results (P1-1.Virtual)
    Reich, Daniel
    Traboulsee, Anthony
    Syed, Sana
    Dukovic, Deborah
    Turner, Timothy
    Arnold, Douglas
    NEUROLOGY, 2022, 98 (18)
  • [32] Long-Term Safety of Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from Phase 3 FREEDOMS II Extension Study
    Vollmer, Timothy
    Jeffery, Douglas
    Goodin, Douglas
    Kappos, Ludwig
    Lublin, Fred
    Radue, Ernst-Wilhelm
    Rammohan, Kottil
    Reder, Anthony
    Agius, Mark
    Stites, Tracy
    Li, Bingbing
    Cappiello, Linda
    von Rosenstiel, Philipp
    Calabresi, Peter
    NEUROLOGY, 2013, 80
  • [33] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Selmaj, K. W.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Minton, N.
    Janjua, A.
    Huang, V.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 548 - 549
  • [34] 4-Year Results from the Long-Term Extension of the Belatacept BENEFIT-EXT Study
    Florman, S.
    Durrbach, A.
    Grinyo, J.
    Pestana, J. O. M.
    Rial, M. d. C.
    Vitko, S.
    Lin, C. -S.
    Harler, M. B.
    Rostaing, L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 82 - 82
  • [35] Magnetic resonance imaging (MRI) outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets: results from the 120-week Phase IIIb extension of the CLARITY study
    Comi, G.
    Giovannoni, G.
    Cook, S.
    Rieckmann, P.
    Rammohan, K.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Martin, E.
    Dangond, F.
    SWISS MEDICAL WEEKLY, 2016, 146 : 77S - 77S
  • [36] Magnetic Resonance Imaging (MRI) Outcomes in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets: Results from the 120-Week Phase IIIb Extension of the CLARITY Study
    Giancarlo, Comi
    Ciovannoni, Gavin
    Cook, Stuart
    Rammohan, Kottil
    Soelberg-Soerensenn, Per
    Vermersch, Patrick
    Martin, Emily
    Dangond, Fernando
    Rieckmann, Peter
    NEUROLOGY, 2016, 86
  • [37] Long-term Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting or Secondary Progressive Multiple Sclerosis: Analysis of Real World Data From the Italian Multiple Sclerosis Registry (CLARINET-MS)
    Patti, Francesco
    Visconti, Andrea
    Capacchione, Antonio
    Trojano, Maria
    NEUROLOGY, 2020, 94 (15)
  • [38] Beyond the Fourth Year: Long-term Outcomes of Cladribine Treatment in Multiple Sclerosis Patients at a Tertiary Care Hospital.
    Bocero Garcia, Antonio
    Lopez Ruiz, Rocio
    Rincon Valencia, Alexandra
    Montero Ramirez, Emilio
    Torres Moral, Alejandro
    Garcia-Soto, Julio Dotor
    Ben-Yelun Insenser, Miriam
    Arzalluz Luque, Joaquin
    Eichau, Sara
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1068 - 1068
  • [39] Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study
    Wiendl, H.
    De Stefano, N.
    Barkhof, F.
    Montalban, X.
    Achiron, A.
    Derfuss, T.
    Chan, A.
    Hodgkinson, S.
    Prat, A.
    Leocani, L.
    Schmierer, K.
    Sellebjerg, F.
    Vermersch, P.
    Jin, H.
    Jaervinen, E.
    Chudecka, A.
    Gardner, L.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 21 - 22
  • [40] Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study
    Wiendl, Heinz
    De Stefano, Nicola
    Barkhof, Frederik
    Montalban, Xavier
    Achiron, Anat
    Derfuss, Tobias
    Chan, Andrew
    Hodgkinson, Suzanne
    Prat, Alexandre
    Leocani, Letizia
    Schmierer, Klaus
    Sellebjerg, Finn
    Vermersch, Patrick
    Jin, Hulin
    Jarvinen, Elina
    Chudecka, Anita
    Gardner, Lidia
    NEUROLOGY, 2023, 100 (17)
12345